Actively Recruiting
PET/CT Characterization of Treatment Resistance
Led by University of Wisconsin, Madison · Updated on 2026-02-17
25
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that assessment. Participants in this study have advanced prostate cancer and are either scheduled to start a second-generation androgen receptor (AR) targeted therapy (such as enzalutamide, abiraterone, or apalutamide) or are already being treated with one. Participants can expect to be in the study for at least 9 months, and up to 2 years.
CONDITIONS
Official Title
PET/CT Characterization of Treatment Resistance
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically proven adenocarcinoma of the prostate.
- At least 1 radiographic metastasis seen on conventional CT imaging or bone scan.
- Progressive prostate cancer with at least two separate increases in PSA over nadir and an absolute PSA value of at least 2 ng/ml for intrinsic resistance cohort.
- Candidate for second-generation androgen receptor inhibitor or Lu177-PSMA radioligand therapy for intrinsic resistance cohort.
- Male aged over 18 years.
- Ability and willingness to lie flat for at least 30 minutes during imaging.
- Informed consent signed after understanding study risks.
- Life expectancy of at least 12 months.
- For acquired resistance cohort, currently receiving second-generation AR inhibitor with prior PSA decline followed by PSA increase within 12 weeks of first documented increase.
You will not qualify if you...
- Uncontrolled diabetes (fasting blood sugar over 200 mg/dL or inability to safely hold diabetes medication or fast 6 hours before FDG PET scan).
- Prior treatment with second-generation AR inhibitor in metastatic setting for intrinsic resistance cohort.
- Pain or symptoms from metastatic prostate cancer requiring opioid analgesics.
- Known neuro-endocrine prostate cancer.
- Prior radioisotope therapy for castration-resistant prostate cancer.
- Vulnerable populations such as incarcerated subjects, those unable to provide informed consent, and non-English speaking patients.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Wisconsin
Madison, Wisconsin, United States, 53705
Actively Recruiting
Research Team
C
Cancer Connect
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here